(Q33897222)

English

Alosetron

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

Europe PubMed Central

Alosetron. (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

Balfour JA

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Goa KL

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Perry CM

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

publication date

1 March 2000

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

59

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

511-8; discussion 519-20

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10776833

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adequate relief as an endpoint in clinical trials in irritable bowel syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/10776833

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea

1 reference

https://pubmed.ncbi.nlm.nih.gov/10776833

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel

1 reference

https://pubmed.ncbi.nlm.nih.gov/10776833

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/10776833

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10776833

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10776833

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review article: clinical pharmacology of alosetron

1 reference

https://pubmed.ncbi.nlm.nih.gov/10776833

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alosetron does not affect the visceral perception of gastric distension in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/10776833

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10776833

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/10776833

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irritable bowel syndrome: a technical review for practice guideline development

1 reference

https://pubmed.ncbi.nlm.nih.gov/10776833

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New drugs in the management of the irritable bowel syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/10776833

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

1 reference

https://pubmed.ncbi.nlm.nih.gov/10776833

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10776833

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-200059030-00008

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33897222&oldid=2195950499"